Today’s News Headlines
Novo Nordisk just threw a major grenade into the GLP-1 price debate: it says the list price for Wegovy, Ozempic, and Rybelsus will drop to $675/month starting January 1, 2027—a move aimed at reducing out-of-pocket pain for people whose cost-sharing is tied to sticker price. (axios.com)
Meanwhile, Eli Lilly’s once-daily oral GLP-1 candidate orforglipron is gaining momentum after Phase 3 results suggesting meaningful weight loss in people with type 2 diabetes—hinting at a future where “needle-free” incretin therapy becomes mainstream. (theguardian.com)
Today’s Top Stories
1) Novo Nordisk plans major U.S. list-price cuts for Wegovy/Ozempic/Rybelsus (effective 2027)
Novo Nordisk announced it will reduce the U.S. wholesale acquisition cost/list price of its semaglutide portfolio to $675 per month starting January 1, 2027. The company says the change is designed to help patients whose out-of-pocket costs are tied to list price (high deductibles/coinsurance), while noting that self-pay channels and existing discount structures may not change much for uninsured patients. (axios.com)
Why it matters: Many people don’t pay “list price,” but list price can still determine what you pay at the pharmacy—this could meaningfully shift affordability for some insured patients. (axios.com)
Source: Axios (Feb 24, 2026). (axios.com)
2) Oral GLP-1 contender: Orforglipron shows 6–8% weight loss in Phase 3 (Achieve-3)
A Phase 3 trial (Achieve-3) reported that once-daily orforglipron led to ~6–8% average weight loss over one year in adults with type 2 diabetes, compared with ~4–5% in those taking oral semaglutide in the comparator group. The trial also noted higher discontinuation in the orforglipron arms due to GI side effects, a reminder that “pill” doesn’t automatically mean “easier.” (theguardian.com)
Why it matters: If future results hold up (including longer-term safety and cardiovascular outcomes), oral incretin options could expand access and convenience for patients who struggle with injections. (theguardian.com)
Source: The Guardian (Feb 26, 2026) + expert reaction (Science Media Centre). (theguardian.com)
3) Intermittent fasting isn’t “better”—major review finds no clear edge vs standard dieting
A new Cochrane review (22 trials, nearly 2,000 adults; up to 12 months) found intermittent fasting did not produce significantly greater weight loss than standard diet advice (and evidence is limited for long-term outcomes beyond a year). The takeaway isn’t “fasting is useless”—it’s that the best plan is the one you can sustain while still achieving a consistent calorie deficit and adequate protein/fiber. (cochrane.org)
Why it matters: This is a helpful reset for anyone feeling like they “failed” because fasting didn’t work—research suggests it’s not magic; it’s just one structure among many. (cochrane.org)
Source: Cochrane (Published Feb 16, 2026). (cochrane.org)
Deep Dive (Weekend Edition: Mindset & Strategy)
“Stop waiting to feel motivated”: the 3-layer plan that actually sticks
Most sustainable weight loss looks boring up close. The people who keep the weight off aren’t relying on hype, pain, or perfect weeks—they’re running a system that makes “good enough” the default.
Here’s a weekend reset you can implement in under 30 minutes:
Layer 1 — The Minimum Viable Day (MVD): pick 3 non-negotiables
Choose three actions that are realistic even on your worst day. Examples:
- Protein anchor: include a protein source at 2 meals (e.g., Greek yogurt, eggs, tofu, chicken, beans).
- Produce floor: 2 servings of fruit/veg (frozen counts).
- Movement dose: 10 minutes of walking—indoors if needed.
Why it works: you’re building identity and consistency, not chasing a perfect calorie number.
Layer 2 — The “Friction Audit”: make the healthier choice easier
Pick one friction point and remove it:
- Put a ready-to-eat protein at eye level (cottage cheese, deli turkey, edamame).
- Batch-cook one high-volume side (roasted veg, soup, salad kit).
- Pre-portion one crunchy snack you actually like (air-popped popcorn, grapes, snap peas).
This aligns with what the research on dieting structures keeps showing: the “best” approach is the one you can adhere to. (That’s also the quiet implication behind the intermittent fasting findings—no special timing strategy wins if adherence collapses.) (cochrane.org)
Layer 3 — The Compassion Script: replace “I blew it” with a next decision
Try this exact reframe:
- Old: “I messed up, so today is ruined.”
- New: “That was one data point. My next decision is a chance to practice.”
This matters because shame predicts more avoidance, and avoidance predicts less adherence. Your plan should assume imperfection—and still function.
If you’re on a GLP-1:
Use the medication’s appetite support to build skills that remain (protein-first meals, regular movement, sleep routine). The WHO’s guidance emphasizes GLP-1s as part of a comprehensive approach—meds can help, but they’re not the whole treatment. (who.int)
Quick Hits
- Novo’s planned list-price cut could reduce out-of-pocket costs particularly for coinsurance/high-deductible designs—but may not change “cash-pay” realities for uninsured patients. (axios.com)
- Employer-benefits analysts are already gaming out what the 2027 price shift means for plan strategy and utilization management. (mercer.com)
- Orforglipron’s “no empty-stomach requirement” is a meaningful usability advantage over oral semaglutide routines—adherence isn’t just willpower; it’s logistics. (theguardian.com)
- Side effects still matter: orforglipron’s higher GI-related discontinuation reminds us that tolerability is a major real-world limiter for incretin therapies. (theguardian.com)
- Intermittent fasting remains a valid preference-based structure for some—but current evidence doesn’t support it as inherently superior for weight loss. (cochrane.org)
- If you’re fasting and struggling: consider a simpler lever—consistent meal patterns with higher protein/fiber can reduce hunger without rigid timing rules. (cochrane.org)
- Reminder: if you’re using GLP-1s, avoid gray-market injections; demand plus shortages have fueled falsified/substandard products, and regulated distribution matters for safety. (who.int)
By The Numbers
22 trials (~2,000 adults): That’s the evidence base in the new Cochrane review evaluating intermittent fasting for overweight/obesity—and it found no clear weight-loss advantage over standard dietary advice up to 12 months. (cochrane.org)
What it means: Intermittent fasting can be a tool, not a tier above other approaches.
Why you should care: If fasting helps you eat less without feeling deprived, great. If it triggers overeating or makes life harder, you’re not “missing the secret”—the evidence says the secret is adherence. (cochrane.org)
Source: Cochrane Database of Systematic Reviews (Published Feb 16, 2026). (cochrane.org)
Ask The Community
What’s your “Minimum Viable Day” for weight loss—the 3 habits you can do even when everything goes sideways?
Tomorrow’s Preview
A practical Sunday playbook: a 45-minute grocery + prep routine that builds high-protein, high-fiber meals for the week—without tracking perfection or cooking every night.